Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Oct 21;14(20):4415.
doi: 10.3390/nu14204415.

Biological Effects of Intravenous Vitamin C on Neutrophil Extracellular Traps and the Endothelial Glycocalyx in Patients with Sepsis-Induced ARDS

Affiliations
Randomized Controlled Trial

Biological Effects of Intravenous Vitamin C on Neutrophil Extracellular Traps and the Endothelial Glycocalyx in Patients with Sepsis-Induced ARDS

Xian Qiao et al. Nutrients. .

Abstract

(1) Background: The disease-modifying mechanisms of high-dose intravenous vitamin C (HDIVC) in sepsis induced acute respiratory distress syndrome (ARDS) is unclear. (2) Methods: We performed a post hoc study of plasma biomarkers from subjects enrolled in the randomized placebo-controlled trial CITRIS-ALI. We explored the effects of HDIVC on cell-free DNA (cfDNA) and syndecan-1, surrogates for neutrophil extracellular trap (NET) formation and degradation of the endothelial glycocalyx, respectively. (3) Results: In 167 study subjects, baseline cfDNA levels in HDIVC (84 subjects) and placebo (83 subjects) were 2.18 ng/µL (SD 4.20 ng/µL) and 2.65 ng/µL (SD 3.87 ng/µL), respectively, p = 0.45. At 48-h, the cfDNA reduction was 1.02 ng/µL greater in HDIVC than placebo, p = 0.05. Mean baseline syndecan-1 levels in HDIVC and placebo were 9.49 ng/mL (SD 5.57 ng/mL) and 10.83 ng/mL (SD 5.95 ng/mL), respectively, p = 0.14. At 48 h, placebo subjects exhibited a 1.53 ng/mL (95% CI, 0.96 to 2.11) increase in syndecan-1 vs. 0.75 ng/mL (95% CI, 0.21 to 1.29, p = 0.05), in HDIVC subjects. (4) Conclusions: HDIVC infusion attenuated cell-free DNA and syndecan-1, biomarkers associated with sepsis-induced ARDS. Improvement of these biomarkers suggests amelioration of NETosis and shedding of the vascular endothelial glycocalyx, respectively.

Keywords: acute respiratory distress syndrome; cell-free DNA; glycocalyx; sepsis; syndecan-1; vitamin C.

PubMed Disclaimer

Conflict of interest statement

M.G.K. received funding from Xellia Pharmaceuticals for serving in the advisory board. J.D.T. received industry-academic funding from Olympus Spiration for serving on a DSMB. G.S.M. received industry-academic funding from The Marcus Foundation, Bristol-Myers Squibb, Cheetah Medical, and Grifols research advisory board funds. J.E.S. received industry-academic funding from The Marcus Foundation, and BARDA. All other authors declare no competing interest.

Figures

Figure 1
Figure 1
Forty-eight-hour change in cell-free DNA (cfDNA) in the two groups, Placebo and HDIVC. Median values, the top and bottom of the boxes show the interquartile range (IQR), whiskers show 95% CI. Outliers outside the 95% confidence intervals were graphically omitted.
Figure 2
Figure 2
Forty-eight-hour increase in syndecan-1 in the two groups, Placebo and HDIVC. Median values, the top and bottom of the boxes show the interquartile range (IQR), whiskers show 95% confidence interval (CI). The extreme outliers outside the 95% confidence intervals have been omitted.
Figure 3
Figure 3
Scatterplot of (a) baseline levels and (b) 48 h levels and (c) 48 h change from baseline, of plasma cfDNA and syndecan-1. The fitted line corresponds to the regression line. Survivors at 7 days are represented with hollow circles, and expired subjects are represented with red crosses (+). Baseline (0 h): Beta = 0.37 p < 0.001 R-Squared = 0.18/48-h: Beta = 0.29, p < 0.001, R-Squared = 0.12/48 h change: Beta = 0.29 p < 0.001 R-Squared = 0.26. Abbreviations: cfDNA, cell-free deoxyribonucleic acid.
Figure 4
Figure 4
Scatterplots of the 48 h change in the PaO2/FiO2 ratio and the change in the plasma syndecan-1 during the same time-period. The figure illustrates the change of the PaO2/FiO2 ratio, a marker of oxygenation and lung injury which corresponds to the change in the plasma biomarker syndecan-1 among the two groups, Placebo and HDIVC. The linear fitted line corresponds to the regression line for each group: Placebo and HDIVC, respectively. The subjects of the placebo group are represented with red x symbols, and the subjects of the HDIVC group are represented with blue triangles. Abbreviations: FiO2, fraction of inspired oxygen; HDIVC, high-dose intravenous vitamin C; PaO2, arterial oxygen pressure.

References

    1. Bellani G., Laffey J.G., Pham T., Fan E., Brochard L., Esteban A., Gattinoni L., Van Haren F., Larsson A., McAuley D.F., et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315:788–800. doi: 10.1001/jama.2016.0291. - DOI - PubMed
    1. Rubenfeld G.D., Caldwell E., Peabody E., Weaver J., Martin D.P., Neff M., Stern E.J., Hudson L.D. Incidence and outcomes of acute lung injury. N. Engl. J. Med. 2005;353:1685–1693. doi: 10.1056/NEJMoa050333. - DOI - PubMed
    1. Matthay M.A., Ware L.B., Zimmerman G.A. The acute respiratory distress syndrome. J. Clin. Investig. 2012;122:2731–2740. doi: 10.1172/JCI60331. - DOI - PMC - PubMed
    1. Fowler A.A., III, Syed A.A., Knowlson S., Sculthorpe R., Farthing D., Dewilde C., Farthing C.A., Larus T.L., Martin E., Brophy D.F., et al. Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis. J. Transl. Med. 2014;12:32. doi: 10.1186/1479-5876-12-32. - DOI - PMC - PubMed
    1. Mohammed B.M., Fisher B.J., Kraskauskas D., Farkas D., Brophy D.F., Fowler A.A., Natarajan R. Vitamin C: A novel regulator of neutrophil extracellular trap formation. Nutrients. 2013;5:3131–3150. doi: 10.3390/nu5083131. - DOI - PMC - PubMed

Publication types